Serious adverse events · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide probably leads to higher serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
≥ 50% reduction in seizure frequency (adults) · people with drug‐resistant focal epilepsy
The intervention probably leads to higher ≥ 50% reduction in seizure frequency (adults) (moderate certainty).
1 finding from 1 review
Intervention not reported
≥ 50% reduction in seizure frequency (children aged 6–18 years) · people with drug‐resistant focal epilepsy
The intervention showed no clear difference in ≥ 50% reduction in seizure frequency (children aged 6–18 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Freedom from seizures · people with drug‐resistant focal epilepsy
The intervention probably leads to higher freedom from seizures (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment withdrawal (any reason) · people with drug‐resistant focal epilepsy
The intervention showed no clear difference in treatment withdrawal (any reason) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment withdrawal (adverse effect) · people with drug‐resistant focal epilepsy
The intervention probably leads to higher treatment withdrawal (adverse effect) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse effects · people with drug‐resistant focal epilepsy
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Treatment withdrawal · people with epilepsy
1 finding from 1 review
Adverse effects (cardiac) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (cardiac) compared with levetiracetam (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (gastrointestinal) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (bones and muscles) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (bones and muscles) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (others) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (others) compared with levetiracetam (low certainty).
1 finding from 1 review
Treatment withdrawal · participants with epilepsy (GTCS)
1 finding from 1 review
Seizure freedom · participants with epilepsy (GTCS)
1 finding from 1 review
All adverse effects · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in all adverse effects compared with phenytoin (low certainty).
1 finding from 1 review
Paraesthesia · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in paraesthesia compared with phenytoin (low certainty).
1 finding from 1 review
Dizziness · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in dizziness compared with phenytoin (low certainty).
1 finding from 1 review
Headache · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in headache compared with phenytoin (low certainty).
1 finding from 1 review
Seizure freedom · people with epilepsy
1 finding from 1 review
Anorexia · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in anorexia compared with phenytoin (low certainty).
1 finding from 1 review